Liquidia: Pay

Liquidia paid its 5 named executives $21.1M in total in FY2025 (Dec). CEO Roger Jeffs, Ph.D. was paid $7.7M of that.

Pay$100 in the stock at the end of FY21 → $708
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Roger Jeffs, Ph.D.Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Michael KasetaChief Financial Officer and Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
3 years
Russell SchundlerGeneral Counsel and Secretary
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Rajeev Saggar, M.D.Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
3 years
Scott MoomawChief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
3 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 5 peers with pay on file was $8.5M. CEO pay of Liquidia for that year is not on file.

  1. 1Kiniksa Pharmaceuticals International
  2. 2Mirum Pharmaceuticals
  3. 3Travere Therapeutics
  4. 4Amphastar Pharmaceuticals
  5. 5Agios Pharmaceuticals
  6. 6LiquidiaNot disclosed
  7. 7Arcturus Therapeutics Holdings Inc.Not disclosed
  8. 8Axsome TherapeuticsNot disclosed
  9. 9Biocryst PharmaceuticalsNot disclosed
  10. 10Catalyst Pharmaceuticals, Inc.Not disclosed
  11. 11MannkindNot disclosed
  12. 12Pacira BioSciencesNot disclosed
  13. 13Rhythm PharmaceuticalsNot disclosed
  14. 14Theravance Biopharma, Inc.Not disclosed
  15. 15Verona Pharma PlcNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.